Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,390.00    108.00 (4.73%)
Bid:
2,380.00
Ask:
2,384.00
Spread: 4.00 (0.168%)
Market Cap: £7.67b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Acquisition

14 Sep 2021 07:00

RNS Number : 6131L
Bunzl PLC
14 September 2021
 

 

14 September 2021

 

BUNZL AGREES TO ACQUIRE US BASED SAFETY BUSINESS AND

HEALTHCARE DISTRIBUTOR IN AUSTRALASIA

 

Bunzl plc, the specialist international distribution and services Group, today announces that it has entered into agreements to acquire a US based safety business and a medical supplies distributor with operations in Australia and Singapore.

 

McCue Corporation ("McCue"), based in Boston, Massachusetts, is a leading business in the distribution of safety and asset protection solutions, and provides Bunzl with a strong position in this fast growing market segment. Supported by a strong portfolio of innovative own brand solutions and smart products, McCue specialises in the distribution of products such as safety barriers, floor railings and bumpers, for use in warehouses and high footfall environments spanning sectors such as grocery and ecommerce. The business has operations in Massachusetts, Texas and California, as well as in the UK and other international markets.

 

The business has delivered very strong double digit annual growth over the last three years. This trajectory continues, supported by the growth in ecommerce-based distribution activities, the importance of health and safety measures in operating environments and the increasing prevalence of higher value warehouse equipment which increases the importance of asset protection. In the 12 months to July 2021 McCue generated revenue of $90 million (c.£65 million), predominantly in the US. The business has an operating margin above the level typically experienced in the Group's safety businesses. The acquisition is subject to competition clearance in the US and is expected to complete later this year.

 

MedShop is an online distributor of medical supplies and devices to a diverse range of healthcare customers, predominately in Australia. The business has a strong digital platform and operations in Melbourne and in Singapore. MedShop generated revenue in 2020 of AUD 22 million (c.£12 million). The acquisition completed in early September.

 

Commenting on the acquisitions, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"The acquisition of McCue represents an exciting expansion of our safety operations in North America and the UK. It is a high quality business with a strong leadership team and track record, with good opportunities for further growth supported by innovation and international expansion. It demonstrates the range of important value-added products and services the Group can provide to customers and our continual focus on evolving our portfolio alongside sector trends.

 

MedShop is a complementary business that builds on our capabilities in the Australian healthcare sector, allowing us to target an expanded customer base. The strength of the digitally focused leadership team supports the significant potential to grow the business in Australasia.

 

Year to date we have now agreed ten acquisitions, with a combined committed spend of approximately £390 million. Our balance sheet remains strong, providing opportunity to self-fund further acquisitions alongside an active pipeline and ongoing discussions."

 

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000

Tulchan

Martin Robinson

Suniti Chauhan

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQLJMATMTBBBTB
Date   Source Headline
3rd Jun 202610:45 amRNSDirector/PDMR Shareholding
1st Jun 202610:15 amRNSTotal Voting Rights
1st Jun 202610:00 amRNSAdmission to Trading
8th May 20264:13 pmRNSDirector/PDMR Shareholding
7th May 20262:43 pmRNSDirector/PDMR Shareholding
6th May 202610:05 amRNSDirector/PDMR Shareholding
1st May 202611:15 amRNSTotal Voting Rights
22nd Apr 20264:15 pmRNSResult of AGM
22nd Apr 20267:00 amRNSTrading Statement
13th Apr 20264:00 pmRNSDirector/PDMR Shareholding
9th Apr 202612:01 pmRNSDirector/PDMR Shareholding
1st Apr 20264:00 pmRNSDirector/PDMR Shareholding
1st Apr 202611:00 amRNSTotal Voting Rights
31st Mar 20264:50 pmRNSDirector/PDMR Shareholding
20th Mar 20262:28 pmRNSDirector/PDMR Shareholding
18th Mar 20265:26 pmRNSDirector/PDMR Shareholding
17th Mar 20264:20 pmRNSAnnual Financial Report
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
16th Mar 20263:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
11th Mar 20264:00 pmRNSDirector/PDMR Shareholding
10th Mar 20263:30 pmRNSDirector Declaration
10th Mar 20263:30 pmRNSDirector Declaration
9th Mar 202610:20 amRNSDirector/PDMR Shareholding
5th Mar 20265:15 pmRNSDirector/PDMR Shareholding
4th Mar 20264:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20264:45 pmRNSDirector/PDMR Shareholding
2nd Mar 202611:00 amRNSTotal Voting Rights
2nd Mar 202610:00 amRNSDividend Declaration
2nd Mar 20267:00 amRNSFinal Results
3rd Feb 20265:00 pmRNSDirector/PDMR Shareholding
2nd Feb 202612:45 pmRNSTotal Voting Rights
13th Jan 20265:00 pmRNSDirector/PDMR Shareholding
7th Jan 20265:15 pmRNSDirector/PDMR Shareholding
6th Jan 202611:15 amRNSDirector/PDMR Shareholding
2nd Jan 202610:45 amRNSTotal Voting Rights
17th Dec 20257:00 amRNSTrading Statement
3rd Dec 202512:00 pmRNSDirector/PDMR Shareholding
1st Dec 202511:00 amRNSTotal Voting Rights
27th Nov 20259:00 amRNSAdditional Listing
26th Nov 20253:34 pmRNSPublication of Admission Particulars.
21st Nov 20255:30 pmRNSHolding(s) in Company
17th Nov 20255:34 pmRNSHolding(s) in Company
13th Nov 20259:00 amRNSAdditional Listing
5th Nov 20259:45 amRNSDirector/PDMR Shareholding
3rd Nov 20254:00 pmRNSHolding(s) in Company
3rd Nov 20253:29 pmRNSTotal Voting Rights
3rd Nov 20259:30 amRNSBlock listing Interim Review
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.